Turning Point Therapeutics Overview
Turning Point Therapeutics (TPTX) has a P/E ratio of -13.04, below the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow-13.04
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Turning Point Therapeutics (TPTX) currently reports a P/E ratio of -13.04. That is below the Healthcare sector average of 26.36. Use the charts on this page to explore Turning Point Therapeutics's P/E ratio history and peer comparisons.
Turning Point Therapeutics's P/E ratio of -13.04 is lower than the Healthcare sector average of 26.36. That is roughly 149.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Turning Point Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -13.04, TPTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -13.04, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for Turning Point Therapeutics, and consider following TPTX for alerts when major investors trade the stock.
Turning Point Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -13.04 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TPTX with unrelated industries.
